Serotonin 5-HT2B inhibitory compounds

Patent metadata

Field	Value
Publication number	US-12240827-B2
Application number	US-202017441340-A
Country	US
Kind code	B2
Filing date	Mar 26, 2020
Priority date	Mar 28, 2019
Publication date	Mar 4, 2025
Grant date	Mar 4, 2025

Abstract

The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably canine.

First claim

We claim:

1. A compound selected from the group consisting of:
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetic acid salt; and
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
and veterinary acceptable salts thereof.

2. A compound of claim 1 , that is
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone or
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
and veterinary acceptable salts thereof.

3. A compound of claim 2 , that is
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
and veterinary acceptable salts thereof.

4. A composition comprising a compound selected from the group consisting of:
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetic acid salt; and
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
and a veterinary acceptable salt thereof.

5. A composition of claim 4 , comprising a compound that is
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone;
and a veterinary acceptable salt thereof.

6. The composition of claim 4 , wherein the composition further comprises at least one veterinary acceptable excipient.

7. The composition of claim 5 , wherein the composition further comprises at least one veterinary acceptable excipient.

Assignees

• Zoetis Services Llc

Inventors

• Ewin Richard Andrew
• Subramanian Govindan
• Deng Jinxia (Nancy)

Classifications

• C07D409/14

  containing three or more hetero rings · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D401/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title